Gale Jesse, Danesh-Meyer Helen V
Auckland District Health Board Ophthalmology Services, Auckland, New Zealand.
Department of Ophthalmology, University of Auckland, Private Bag 92019, Auckland Mail Centre, Auckland 1142, New Zealand.
J Clin Neurosci. 2014 Feb;21(2):195-7. doi: 10.1016/j.jocn.2013.11.009. Epub 2013 Dec 8.
The 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, or statins, are commonly prescribed for prevention of cardiovascular morbidity. A rare side effect of statin medication is the induction of autoimmune illnesses, including myasthenia gravis (myasthenia). Here we present two patients with seropositive myasthenia that developed 4 weeks after initiation of atorvastatin, increasing the total reported patients to seven. Reviewing recent literature we highlight the connections between statins, auto-immunity and myasthenia. Statins may favour T-cell phenotypes that reduce cell-mediated immunity but could increase antibody-mediated humoral immunity.
3-羟基-3-甲基戊二酰辅酶A(HMG-CoA)还原酶抑制剂,即他汀类药物,常用于预防心血管疾病。他汀类药物的一种罕见副作用是诱发自身免疫性疾病,包括重症肌无力(肌无力)。在此,我们报告两例血清学阳性的肌无力患者,在开始服用阿托伐他汀4周后发病,使报告的患者总数增至7例。回顾近期文献,我们强调了他汀类药物、自身免疫和肌无力之间的联系。他汀类药物可能有利于减少细胞介导免疫的T细胞表型,但可能会增加抗体介导的体液免疫。